Deutsche Bank AG Boosts Stake in InMode Ltd. (NASDAQ:INMD)

Deutsche Bank AG raised its holdings in InMode Ltd. (NASDAQ:INMD - Free Report) by 52.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 66,700 shares of the healthcare company's stock after purchasing an additional 22,820 shares during the quarter. Deutsche Bank AG owned 0.10% of InMode worth $1,114,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of INMD. Crestline Management LP bought a new position in InMode in the fourth quarter valued at about $559,000. Bridgefront Capital LLC acquired a new stake in InMode in the fourth quarter valued at $178,000. Cary Street Partners Financial LLC acquired a new stake in shares of InMode in the fourth quarter valued at about $2,214,000. BNP Paribas Financial Markets bought a new position in InMode during the 4th quarter worth approximately $954,000. Finally, Ameriprise Financial Inc. lifted its holdings in InMode by 1.9% in the fourth quarter. Ameriprise Financial Inc. now owns 233,621 shares of the healthcare company's stock valued at $3,901,000 after buying an additional 4,308 shares during the period. Institutional investors own 68.04% of the company's stock.

Analysts Set New Price Targets

INMD has been the subject of several research reports. Barclays reduced their target price on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Jefferies Financial Group decreased their price objective on shares of InMode from $16.00 to $15.00 and set a "hold" rating for the company in a report on Monday, April 14th. Baird R W cut InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research report on Monday, April 28th. Finally, Robert W. Baird cut shares of InMode from an "outperform" rating to a "neutral" rating and reduced their price objective for the company from $22.00 to $16.00 in a research note on Monday, April 28th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, InMode presently has a consensus rating of "Hold" and an average price target of $18.54.

InMode Price Performance

NASDAQ:INMD traded down $0.06 during mid-day trading on Friday, hitting $14.53. 132,756 shares of the company's stock were exchanged, compared to its average volume of 1,224,127. The company has a market cap of $918.17 million, a PE ratio of 6.18 and a beta of 2.02. InMode Ltd. has a one year low of $13.68 and a one year high of $19.85. The business has a fifty day moving average price of $15.27 and a 200 day moving average price of $17.10.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The company had revenue of $77.87 million for the quarter, compared to analysts' expectations of $82.21 million. During the same quarter in the previous year, the firm posted $0.32 EPS. The firm's quarterly revenue was down 3.0% compared to the same quarter last year. On average, equities analysts forecast that InMode Ltd. will post 1.75 EPS for the current fiscal year.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.